Production (Stage)
Beam Therapeutics Inc.
BEAM
$16.83
-$0.41-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.38% | -83.18% | 328.73% | 339.83% | 370.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.38% | -83.18% | 328.73% | 339.83% | 370.57% |
| Cost of Revenue | -16.01% | -31.32% | -11.63% | -6.52% | 2.76% |
| Gross Profit | -4,346.94% | -296.95% | 103.52% | 102.69% | 102.06% |
| SG&A Expenses | -6.09% | -4.53% | 31.05% | 34.95% | 30.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.90% | -13.55% | 10.93% | 16.35% | 23.92% |
| Operating Income | -137.07% | -135.47% | 54.14% | 51.64% | 49.70% |
| Income Before Tax | -190.40% | -187.21% | 54.53% | 56.26% | 57.38% |
| Income Tax Expenses | -97.14% | -97.14% | 40.50% | -58.80% | -59.94% |
| Earnings from Continuing Operations | -187.48% | -184.28% | 54.22% | 56.29% | 57.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.48% | -184.28% | 54.22% | 56.29% | 57.41% |
| EBIT | -137.07% | -135.47% | 54.14% | 51.64% | 49.70% |
| EBITDA | -154.02% | -151.57% | 57.65% | 55.31% | 53.46% |
| EPS Basic | -164.76% | -144.95% | 58.80% | 60.96% | 60.93% |
| Normalized Basic EPS | -157.45% | -156.13% | 65.70% | 69.07% | 64.39% |
| EPS Diluted | -158.78% | -139.79% | 57.80% | 60.05% | 60.00% |
| Normalized Diluted EPS | -151.73% | -150.40% | 64.84% | 68.30% | 63.58% |
| Average Basic Shares Outstanding | 5.54% | 6.73% | 9.67% | 11.79% | 12.10% |
| Average Diluted Shares Outstanding | 4.93% | 6.09% | 10.29% | 12.43% | 12.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |